Ligand id: 6780

Name: rituximab

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: rituximab

Compound class Antibody
Approved drug? Yes (FDA (1997), EMA (1998))
International Nonproprietary Names
INN number INN
7609 rituximab
HSDB 7455 | MabThera® | Rituxan®
Database Links
Specialist databases
IMGT/mAb-DB 161
Other databases
GtoPdb PubChem SID 178103386
PubChem SID 178103386
Search PubMed clinical trials rituximab
Search PubMed titles rituximab
Search PubMed titles/abstracts rituximab
Wikipedia Rituximab
Rituximab is a type I anti-CD20 monoclonal, designed to target surface CD20 on B-lymphocytes. It is a cancer and autoimmune disease drug.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

Blitzima (CT-P10, a.k.a. Truxima, Tuxella and Ritemvia; developed by Celltrion) gained EMA approval in February 2017 [4].
Pfizer's PF-05280586 is in early stage development [9] (evaluated in completed clinical trial NCT01526057 Phase 1/2).
AcellBia (BCD-020, by Biocad and approved in 2014 by the Ministry of Health of the Russian Federation) is in Phase 3 clinical trial -see NCT02744196 and NCT01759030 as examples.
GP2013 (Sandoz) has completed Phase 3 rheumatoid arthritis clinical trial NCT02514772 in direct comparision with the originator product.
SAIT101 is in a Phase 3 comparision clinical trial with MabThera® for follicular lymphoma (NCT02809053), and Phase 1 trial NCT02819726 for rheumatoid arthritis.